Brolucizumab (Alcon, a division of Novartis, Fort Worth, TX, USA) has shown preliminary efficacy and safety and appears to be a strong anti-VEGF drug designed for the treatment of neovascular age-related macular degeneration. The gene discussed is VEGFA; the disease is age-related macular degeneration.